Capstone Therapeutics (CAPS) Expected to Announce Quarterly Earnings on Friday

Capstone Therapeutics (NASDAQ:CAPS) is expected to release its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Capstone Therapeutics to post earnings of $5.70 per share and revenue of $24.60 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 18, 2026 at 9:30 AM ET.

Capstone Therapeutics Stock Performance

NASDAQ:CAPS opened at $2.07 on Thursday. The business has a 50 day simple moving average of $4.24 and a 200 day simple moving average of $10.74. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.39 and a current ratio of 0.99. Capstone Therapeutics has a 12-month low of $1.92 and a 12-month high of $34.80.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Capstone Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury.

The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.